Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Highlights of the conference coverage from the 2025 European Society of Medical Oncology (ESMO) Congress included content on ...

At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen ...

Former BYU linebacker Larry Carr's tireless crusade to save football and football players — and anyone else with a brain injury — received a big shot in the arm last month. Two shots, actually.

PERSEUS trial findings suggest that modern myeloma therapies could lead to survival rates similar to age-matched controls. KLN-1010, an off-the-shelf gene therapy, demonstrated promising MRD-negative ...

Proton radiotherapy (RT) for oropharyngeal cancer matched conventional photon therapy for slowing disease progression and led ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

The FDA has cleared the initiation of a pivotal Phase 3 trial testing pridopidine in people with early, rapidly progressive ...

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and ...

Sacituzumab govitecan showed lower rates of dose reductions and treatment discontinuations due to adverse effects compared to chemotherapy in TNBC patients. Common adverse effects, such as diarrhea ...

Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome. Read why KYTX ...